Showing 1041-1050 of 20877 results for "".
- Low Infection Risk Across Psoriasis Biologics Reported in Real-World Studyhttps://reachmd.com/news/low-infection-risk-across-psoriasis-biologics-reported-in-real-world-study/2487541/A large real-world analysis published in the Journal of the American Academy of Dermatology indicates biologic therapies for psoriasis are associated with low overall infection risk, with ustekinumab and interleukin (IL)-23
- Paroxetine Linked to Neurovascular and Immune Proteomic Changes in Refractory Rosacea: Analysishttps://reachmd.com/news/paroxetine-linked-to-neurovascular-and-immune-proteomic-changes-in-refractory-rosacea/2487517/A secondary analysis of a randomized clinical trial in JAMA Dermatology identified systemic proteomic changes associated with paroxetine treatment in patients with refractory erythematous rosacea, offering new insight into
- Intermittent Daily Isotretinoin Matches Alternate-Day Regimen in Grade 2 Acne Trialhttps://reachmd.com/news/intermittent-daily-isotretinoin-matches-alternate-day-regimen-in-grade-2-acne-trial/2487522/A randomized controlled trial published in the Indian Journal of Medical Research found that an intermittent daily isotretinoin regimen was non-inferior to a continuous alternate-day regimen for the treatment of grade 2 facial acne vulgaris, while also offering lower treatment costs.¹ Rese
- FAST III: Angiography-Based Physiology vs Pressure-Wire Guidancehttps://reachmd.com/news/fast-iii-angiography-physiology-pressure-wire/2487510/Key Takeaways vFFR-guided and FFR-guided strategies had the same reported 1-year primary-endpoint rate, and the authors concluded noninferiority. FAST III was an international, open-label, randomized noninferiority trial at 37 European sites in patient
- Olaparib Plus Radium-223 Improves rPFS in COMRADEhttps://reachmd.com/news/olaparib-radium-223-rpfs-comrade/2487511/Key Takeaways Olaparib plus radium-223 was associated with longer investigator-assessed radiographic progression-free survival than radium-223 alone. Longer radiographic progression-free survival was most pronounced without prior docetaxel and with 20
- Induction Therapies Launches Recovery Serum for At-Home Skincare Supporthttps://reachmd.com/news/induction-therapies-launches-recovery-serum-for-at-home-skincare-support/2487505/Induction Therapies has introduced YouthXO + PDRN, a new recovery and renewal serum designed to support skin health between professional aesthetic treatments and as part of a daily skincare regimen. According to the company, the serum combines plant exosomes, vegan polydeoxyribonucleotide
- Cagrilintide-Semaglutide Added to Basal Insulin in REIMAGINE 3https://reachmd.com/news/cagrilintide-semaglutide-added-to-basal-insulin-in-reimagine-3/2487497/Key Takeaways Once-weekly cagrilintide-semaglutide added to basal insulin was associated with larger week-40 HbA1c reductions than placebo. Body weight decreased by 10% to 12% across the active-dose groups. Adverse events were mostly mild or m
- Early SGLT2 Inhibitor Use in Takotsubo Syndromehttps://reachmd.com/news/early-sglt2-inhibitor-use-in-takotsubo-syndrome/2487495/Key Takeaways Early SGLT2 inhibitor use was associated with lower all-cause mortality in the propensity-matched analysis. No significant associations were reported for heart failure hospitalization, cardiogenic shock, cardiac arrest, or major adverse c
- Ensitrelvir Did Not Improve Recovery in Hospitalized Adults With Covid-19https://reachmd.com/news/ensitrelvir-did-not-improve-recovery-in-hospitalized-adults-with-covid-19/2487487/Key Takeaways Ensitrelvir plus standard of care was not associated with a significant improvement in clinical recovery through day 60 compared with placebo plus standard of care. Detectable plasma viral antigen at day 5 was lower with ensitrelvir, but
- Higher Intraoperative Blood Pressure Targets in Noncardiac Surgeryhttps://reachmd.com/news/higher-intraoperative-blood-pressure-targets-in-noncardiac-surgery/2487499/Key Takeaways Higher targets were not associated with less acute kidney injury or acute myocardial injury, and trial sequential analysis supported those null findings. No significant effect was observed for in-hospital or 30-day mortality, while eviden